26 results on '"Evans, D. G."'
Search Results
2. Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD).
- Author
-
Ramchander, N. C., Ryan, N. A. J., Crosbie, E. J., and Evans, D. G.
- Subjects
ANTIBODY diversity ,GENETIC mutation ,DNA repair ,AUTOSOMAL recessive polycystic kidney - Abstract
Background: Constitutional mismatch repair deficiency syndrome results from bi-allelic inheritance of mutations affecting the key DNA mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. Individuals with bi-allelic mutations have a dysfunctional mismatch repair system from birth; as a result, constitutional mismatch repair deficiency syndrome is characterised by early onset malignancies. Fewer than 150 cases have been reported in the literature over the past 20 years. This is the first report of the founder PMS2 mutation - NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon 11 and its associated cancers in this family. Case presentation: The proband is 30 years old and is alive today. She is of Pakistani ethnic origin and a product of consanguinity. She initially presented aged 24 with painless bleeding per-rectum from colorectal polyps and was referred to clinical genetics. Clinical examination revealed two café-au-lait lesions, lichen planus, and a dermoid cyst. Her sister had been diagnosed in childhood with an aggressive brain tumour followed by colorectal cancer. During follow up, the proband developed 37 colorectal adenomatous polyps, synchronous ovarian and endometrial adenocarcinomas, and ultimately a metachronous gastric adenocarcinoma. DNA sequencing of peripheral lymphocytes revealed a bi-allelic inheritance of the PMS2 mutation NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon 11. Ovarian tumour tissue demonstrated low microsatellite instability. To date, she has had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and a total gastrectomy. Aspirin and oestrogen-only hormone replacement therapy provide some chemoprophylaxis and manage postmenopausal symptoms, respectively. An 18-monthly colonoscopy surveillance programme has led to the excision of three high-grade dysplastic colorectal tubular adenomatous polyps. The proband's family pedigree displays multiple relatives with cancers including a likely case of 'true' Turcot syndrome. Conclusions: Constitutional mismatch repair deficiency syndrome should be considered in patients who present with early onset cancer, a strong family history of cancer, and cutaneous features resembling neurofibromatosis type I. Immunohistochemistry analysis of tumour and normal tissue is sensitive and specific for identifying patients with mismatch repair deficiency and should direct DNA sequencing of lymphocytic tissue to establish a diagnosis. Microsatellite instability status appears to be of little value in identifying patients who may have constitutional mismatch repair deficiency syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. The BRCA2 polymorphic stop codon: stuff or nonsense?
- Author
-
Higgs, J. E., Harkness, E. F., Bowers, N. L., Howard, E., Wallace, A. J., Lalloo, F., Newman, W. G., and Evans, D. G.
- Subjects
GENETIC polymorphisms ,GENETIC code ,BRCA genes ,NUCLEIC acid isolation methods ,CANCER risk factors ,GENETIC mutation - Abstract
Background Despite classification of the BRCA2c.9976A>T, p.(Lys3326Ter) variant as a polymorphism, it has been associated with increased risks of pancreatic, lung, oesophageal and breast cancer. Methods We have noticed multiple co-occurrences of the BRCA2 c.9976A>T variant with the pathogenic BRCA2c.6275_6276delTT frameshift mutation p. (Leu2092ProfsTer7) and using a cohort study have assessed if this might account for these tumour risk associations. Results We identified 52 families with BRCA2c.6275_6276delTT, all of which occur in cis with the BRCA2c.9976A>T variant allele as demonstrated by co-segregation in all family members tested. Of 3245 breast/ovarian cancer samples sequenced for BRCA2, only 43/3245 (1.3%) carried BRCA2 c.9976A>T alone, after excluding individuals with BRCA2c.6275_6276delTT (n=22) or other BRCA1 (n=3) or BRCA2 (n=2) pathogenic mutations. The resultant frequency (1.3%) after removal of co-occurring mutations is lower than the 1.7% and 1.67% frequencies from two control populations for BRCA2 c.9976A>T, but similar to the 1.39% seen in the Exome Aggregation Consortium database. We did not identify increased frequencies of oesophageal, pancreatic or lung cancer in families with just BRCA2 c.9976A>T using person-years at risk analysis. Conclusions It is likely that the previous associations of increased cancer risks due to BRCA2c.9976A>T represent reporting bias and are contributed to because the variant is in LD with BRCA2c.6275_6276delTT. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
- Author
-
Newton, K., Jorgensen, N. M., Wallace, A. J., Buchanan, D. D., Lalloo, F., McMahon, R. F. T., Hill, J., and Evans, D. G.
- Subjects
MLH1 gene ,CANCER genes ,HEREDITARY nonpolyposis colorectal cancer ,DISEASE incidence ,GENETIC mutation ,MEDICAL genetics - Abstract
Background and aims Lynch syndrome (LS) patients have DNA mismatch repair deficiency and up to 80% lifetime risk of colorectal cancer (CRC). Screening of mutation carriers reduces CRC incidence and mortality. Selection for constitutional mutation testing relies on family history (Amsterdam and Bethesda Guidelines) and tumour-derived biomarkers. Initial biomarker analysis uses mismatch repair protein immunohistochemistry and microsatellite instability. Abnormalities in either identify mismatch repair deficiency but do not differentiate sporadic epigenetic defects, due to MLH1 promoter region methylation (13% of CRCs) from LS (4% of CRCs). A diagnostic biomarker capable of making this distinction would be valuable. This study compared two biomarkers in tumours with mismatch repair deficiency; quantification of methylation of the MLH1 promoter region using a novel assay and BRAF c.1799T>A, p.(Val600Glu) mutation status in the identification of constitutional mutations. Methods Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to test for MLH1 promoter methylation and presence of the BRAF c.1799T>A, p.(Val600Glu) mutation 71 CRCs from individuals with pathogenic MLH1 mutations and 73 CRCs with sporadic MLH1 loss. Specificity and sensitivity was compared. Findingss Unmethylated MLH1 promoter: sensitivity 94.4% (95% CI 86.2% to 98.4%), specificity 87.7% (95% CI 77.9% to 94.2%), Wild-type BRAF (codon 600): sensitivity 65.8% (95% CI 53.7% to 76.5%), specificity 98.6% (95% CI 92.4% to 100.0%) for the identification of those with pathogenic MLH1 mutations. Conclusions Quantitative MLH1 promoter region methylation using pyrosequencing is superior to BRAF codon 600 mutation status in identifying constitutional mutations in mismatch repair deficient tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
- Author
-
Robertson, L, Hanson, H, Seal, S, Warren-Perry, M, Hughes, D, Howell, I, Turnbull, C, Houlston, R, Shanley, S, Butler, S, Evans, D G, Ross, G, Eccles, D, Tutt, A, and Rahman, N
- Subjects
BREAST cancer diagnosis ,CANCER in women ,BRCA genes ,HUMAN chromosome abnormality diagnosis ,GENETIC mutation - Abstract
Background:Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer.Methods:We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.Results:BRCA1 mutations were present in 45 out of 308 individuals. Individuals with TN cancer <50 years had >10% likelihood of carrying a BRCA1 mutation in both the unselected (11 out of 58, 19%) and selected (26 out of 111, 23%) series. However, over a third would not have been offered testing using existing criteria. We estimate that testing all individuals with TN breast cancer <50 years would generate an extra 1200 tests annually in England.Conclusion:Women with TN breast cancer diagnosed below 50 years have >10% likelihood of carrying a BRCA1 mutation and are therefore eligible for testing in most centres. However, implementation may place short-term logistical and financial burdens on genetic services. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
- Author
-
Mitra, Anita V., Bancroft, Elizabeth K., Barbachano, Yolanda, Page, Elizabeth C., Foster, C. S., Jameson, C., Mitchell, G., Lindeman, G. J., Stapleton, A., Suthers, G., Evans, D. G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., and Douglas, F.
- Subjects
PROSTATE cancer ,CANCER in men ,MEDICAL screening ,GENETIC mutation ,PROSTATE-specific antigen ,FAMILIAL diseases ,GENETIC disorders - Abstract
OBJECTIVE To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA >3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47∙6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
- Author
-
Hadfield, K D, Smith, M J, Urquhart, J E, Wallace, A J, Bowers, N L, King, A T, Rutherford, S A, Trump, D, Newman, W G, and Evans, D G
- Subjects
GENETIC recombination ,ACOUSTIC neuroma ,HETEROZYGOSITY ,GENETIC mutation ,MICROSATELLITE repeats ,NUCLEOTIDE sequence ,EXONS (Genetics) - Abstract
Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
- Author
-
Edwards, S. M., Evans, D. G. R., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., Kote-Jarai, Z., Meitz, J., Falconer, A., Osin, P., Fisher, C., Guy, M., Jhavar, S. G., Hall, A. L., O'Brien, L. T., Gehr-Swain, B. N., Wilkinson, R. A., Forrest, M. S., Dearnaley, D. P., and Ardern-Jones, A. T.
- Subjects
- *
PROSTATE cancer , *GERM cells , *GENETIC mutation , *GENETICS , *PROGNOSIS , *HETEROZYGOSITY , *DNA , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PROSTATE tumors , *RESEARCH , *RESEARCH funding , *SURVIVAL analysis (Biometry) , *EVALUATION research , *BRCA genes - Abstract
Background: The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours.Methods: Two cohorts were compared: one was a group with young-onset PrCa, tested for germline BRCA2 mutations (6 of 263 cases had a germline BRAC2 mutation), and the second was a validation set consisting of a clinical set from Manchester of known BRCA2 mutuation carriers (15 cases) with PrCa. Survival data were compared with a control series of patients in a single clinic as determined by Kaplan-Meier estimates. Loss of heterozygosity was tested for in the DNA of tumour tissue of the young-onset group by typing four microsatellite markers that flanked the BRCA2 gene, followed by sequencing.Results: Median survival of all PrCa cases with a germline BRCA2 mutation was shorter at 4.8 years than was survival in controls at 8.5 years (P=0.002). Loss of heterozygosity was found in the majority of tumours of BRCA2 mutation carriers. Multivariate analysis confirmed that the poorer survival of PrCa in BRCA2 mutation carriers is associated with the germline BRCA2 mutation per se.Conclusion: BRCA2 germline mutation is an independent prognostic factor for survival in PrCa. Such patients should not be managed with active surveillance as they have more aggressive disease. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
9. Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives.
- Author
-
Evans, D. G. R., Binchy, A., Shenton, A., Hopwood, P., and Craufurd, D.
- Subjects
- *
BREAST cancer , *PREDICTIVE tests , *GENETIC mutation , *CANCER invasiveness , *HUMAN chromosome abnormality diagnosis - Abstract
There have been few studies addressing uptake of predictive testing for BRCA1/2, only one comparing a proactive with usual family networking approach to dissemination. We report uptake of predictive genetic testing after directly offering BRCA1 presymptomatic genetic testing to 100 individuals in two generations of 5 large BRCA1 families compared with service testing of 196 families since that time. Uptake was significantly higher in the first generation (group 1), who were directly offered testing, and much higher in females. Seventy-four percent of unaffected women in the first generation proceeded to testing, 42% of men. This decreased to 44% of women in the second generation (group 2) and 9% males (p = 0.0003). Uptake in unaffected individuals in the final group (group 3) with no proactive approach was significantly lower than that in the first group. Overall uptake after 10 years was 56% (95% confidence interval, CI, 50–62%) for group 1 and 36% (95% CI 34.3–37.7%) for 1084 group 3 individuals (p = 0.0003). Among women, uptake was 74% (95% CI 67–81%) in group 1 at 10 years compared with 51.5% (95% CI 49–54%) in 552 group 3 women (p = 0.023). In men, uptake was 42% (95% CI 33–52%) in group 1 and 21.1% (95% CI 18.1–23.1%) among 532 men in group 3 (p = 0.0098). Although these results are not from a randomized trial, they show particularly among men a substantially higher uptake of genetic services with a direct approach. Importance should be given to more proactive approaches to ensure that men in BRCA1/2-positive families receive the appropriate information. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
10. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
- Author
-
Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., Hill, J., and Evans, D. G.
- Subjects
GENETIC research ,COLON cancer ,GENETIC mutation ,DNA repair ,IMMUNOHISTOCHEMISTRY - Abstract
Lynch syndrome or hereditary non-polyposis colorectal cancer is caused by mutations of DNA mismatch repair (MMR) genes. The extracolonic tumour spectrum includes endometrial, ovarian, gastric, small bowel, pancreatic, hepatobiliary, brain, and urothelial neoplasms. Families were referred on the basis of clinical criteria. Tumour immunohistochemistry and microsatellite testing were performed. Appropriate patients underwent sequencing of relevant exons of the MMR genes. Proven and obligate mutation carriers and first-degree relatives (FDRs) with a Lynch syndrome spectrum cancer were considered mutation carriers, as were a proportion of untested, unaffected FDRs based on the proportion of unaffected relatives testing positive in each age group. Kaplan–Meier analysis of risk to 70 years was calculated. One hundred and eighty-four Lynch syndrome spectrum extracolonic cancers in 839 proven, obligate, or assumed mutation carriers were analysed. Cumulative risk for females of an extracolonic tumour is 47.4% (95% CI 43.9–50.8). The risk to males is 26.5% (95% CI 22.6–30.4). There was no reduction in gynaecological malignancies due to gynaecological screening (examination, transvaginal ultrasound scan, hysteroscopy and endometrial biopsy). Males have a higher risk of gastric cancer than females (p = 0.0003). Gastric cancer risk in those born after 1935 does not justify surveillance. These penetrance estimates have been corrected for ascertainment bias and are appropriate for those referred to a high-risk clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
- Author
-
Antoniou, A. C., Hardy, A., Walker, L., Evans, D. G., Shenton, A., Eeles, R., Shanley, S., Pichert, G., Lzatt, L., Rose, S., Douglas, F., Eccles, D., Morrison, P. J., Scott, J., Zimmern, A. L., Easton, D. F., and Pharoah, P. D. P.
- Subjects
HUMAN chromosome abnormality diagnosis ,BREAST cancer ,OVARIAN cancer ,GENETIC mutation ,CANCER susceptibility - Abstract
Objectives: Genetic testing for the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 has important implications for the clinical management of people found to carry a mutation. However, genetic testing is expensive and may be associated with adverse psychosocial effects. To provide a cost-efficient and clinically appropriate genetic counselling service, genetic testing should be targeted at those individuals most likely to carry pathogenic mutations. Several algorithms that predict the likelihood of carrying a BRCA1 or a BRCA2 mutation are currently used in clinical practice to identify such individuals. Design: We evaluated the performance of the carrier prediction algorithms BOADICEA, BRCAPRO, IBIS, the Manchester scoring system and Myriad tables, using 1934 families seen in cancer genetics clinics in the UK in whom an index patient had been screened for BRCA1 and/or BRCA2 mutations. The models were evaluated for calibration, discrimination and accuracy of the predictions. Results: Of the five algorithms, only BOADICEA predicted the overall observed number of mutations detected accurately (ie, was well calibrated). BOADICEA also provided the best discrimination, being significantly better (p<0.05) than all models except BRCAPRO (area under the receiver operating characteristic curve statistics: BOADICEA = 0.77, BRCAPRO = 0.76, IBIS = 0.74, Manchester = 0.75, Myriad = 0.72). All models under-predicted the number of BRCA 1 and BRCA2 mutations in the low estimated risk category. Conclusions: Carrier prediction algorithms provide a rational basis for counselling individuals likely to carry BRCA1 or BRCA2 mutations. Their widespread use would improve equity of access and the cost-effectiveness of genetic testing. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
12. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
- Author
-
Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Southey, M. C., Olsson, H., Johannsson, O., Borg, A., Passini, B., Radice, P., Manoukian, S., Eccles, D. M., Tang, N., Olah, E., and Anton-Culver, H.
- Subjects
CANCER susceptibility ,CANCER in women ,BREAST cancer ,MALE reproductive organs ,CANCER patients ,DRUG therapy ,AGE distribution ,BIOLOGICAL models ,BREAST tumors ,COMPARATIVE studies ,DISEASE susceptibility ,GENETIC techniques ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,OVARIAN tumors ,RESEARCH ,RESEARCH funding ,EVALUATION research ,BRCA genes ,SECONDARY primary cancer - Abstract
Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously developed a model (BOADICEA) under which susceptibility to breast cancer is explained by mutations in BRCA1 and BRCA2, as well as by the joint multiplicative effects of many genes (polygenic component). We have now updated BOADICEA using additional family data from two UK population-based studies of breast cancer and family data from BRCA1 and BRCA2 carriers identified by 22 population-based studies of breast or ovarian cancer. The combined data set includes 2785 families (301 BRCA1 positive and 236 BRCA2 positive). Incidences were smoothed using locally weighted regression techniques to avoid large variations between adjacent intervals. A birth cohort effect on the cancer risks was implemented, whereby each individual was assumed to develop cancer according to calendar period-specific incidences. The fitted model predicts that the average breast cancer risks in carriers increase in more recent birth cohorts. For example, the average cumulative breast cancer risk to age 70 years among BRCA1 carriers is 50% for women born in 1920-1929 and 58% among women born after 1950. The model was further extended to take into account the risks of male breast, prostate and pancreatic cancer, and to allow for the risk of multiple cancers. BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html). [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
13. Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations.
- Author
-
Speake, D., Evans, D. G., Lalloo, F., Scott, N. A., and Hill, J.
- Subjects
- *
POLYPS , *GENETIC mutation , *MESENTERY , *SURGERY , *TUMORS , *ABDOMINAL surgery , *ENDOSCOPIC surgery , *DISEASES - Abstract
Background: The aim of this study was to determine the proportion of patients with familial adenomatous polyposis (FAP) who had mutations in the desmoid region of the adenomatous polyposis coli (APC) gene that phenotypically expresses desmoid disease, and to determine the role for surgery in these patients. Methods: Data from the North West Region FAP database and case notes were analysed retrospectively. Results: Of 363 patients with FAP, 47 from ten families had APC mutations in the desmoid region 3′ to codon 1399. Of 22 patients undergoing surgery, 16 developed desmoids, and of these 12 had mesenteric desmoid disease. Complications from mesenteric desmoids were death (two patients), enterectomy (three), local resection (three), fistula (one), cholangitis and local resection (one), bowel obstruction (one) and bowel and ureteric obstruction (one). Preoperative polyp burden ranged from 0 to 100 in eight patients (median age 24.5 (range 16-39) years) and more than 100 in seven (median age 39 (range 31-64) years). One patient had no record of polyp burden. Conclusion: In individuals with 3′ APC mutations, abdominal surgery is associated with a 65 per cent risk of developing mesenteric desmoids. An alternative strategy might be to attempt to manage the polyps endoscopically. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
14. Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
- Author
-
Foster, C., Watson, M., Eeles, R., Eccles, D., Ashley, S., Davidson, R., Mackay, J., Morrison, P. J., Hopwood, P., Evans, D. G. R., and Psychosocial Study Collaborators
- Subjects
BRCA genes ,GENETIC mutation ,DISEASE risk factors ,HUMAN chromosome abnormality diagnosis ,BREAST cancer ,CANCER in women ,BREAST tumor prevention ,RESEARCH ,OVARIAN tumors ,RESEARCH methodology ,GENETIC testing ,MAMMOGRAMS ,EVALUATION research ,GENETIC carriers ,COMPARATIVE studies ,DISEASE susceptibility ,OVARIECTOMY ,RISK management in business ,PATIENT compliance ,DISCRIMINATION in insurance ,BREAST tumors ,PROSTATE tumors - Abstract
This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response) participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation. In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms compared with 47% non-carriers. Thirty-six per cent non-carriers > or =50 years did not have a mammogram post-test. Twenty-two per cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help some women understand the meaning of their genetic status. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
15. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
- Author
-
Griebsch, I., Brown, J., Boggis, C., Dixon, A., Dixon, M., Easton, D., Eeles, R., Evans, D. G., Gilbert, F. J., Hawnaur, J., Kessar, P., Lakhani, S. R., Moss, S. M., Nerurkar, A., Padhani, A. R., Pointon, L. J., Potterton, J., Thompson, D., Turnbull, L. W., and Walker, L. G.
- Subjects
BREAST cancer ,CANCER in women ,MAMMOGRAMS ,MAGNETIC resonance mammography ,DIAGNOSIS ,BREAST tumor diagnosis ,X-rays ,PROTEINS ,RESEARCH ,GENETIC mutation ,RESEARCH methodology ,MAGNETIC resonance imaging ,MEDICAL screening ,EVALUATION research ,DIAGNOSTIC imaging ,COST benefit analysis ,COMPARATIVE studies ,DISEASE susceptibility ,BREAST tumors - Abstract
Contrast enhanced magnetic resonance imaging (CE MRI) is the most sensitive tool for screening women who are at high familial risk of breast cancer. Our aim in this study was to assess the cost-effectiveness of X-ray mammography (XRM), CE MRI or both strategies combined. In total, 649 women were enrolled in the MARIBS study and screened with both CE MRI and mammography resulting in 1881 screens and 1–7 individual annual screening events. Women aged 35–49 years at high risk of breast cancer, either because they have a strong family history of breast cancer or are tested carriers of a BRCA1, BRCA2 or TP53 mutation or are at a 50% risk of having inherited such a mutation, were recruited from 22 centres and offered annual MRI and XRM for between 2 and 7 years. Information on the number and type of further investigations was collected and specifically calculated unit costs were used to calculate the incremental cost per cancer detected. The numbers of cancer detected was 13 for mammography, 27 for CE MRI and 33 for mammography and CE MRI combined. In the subgroup of BRCA1 (BRCA2) mutation carriers or of women having a first degree relative with a mutation in BRCA1 (BRCA2) corresponding numbers were 3 (6), 12 (7) and 12 (11), respectively. For all women, the incremental cost per cancer detected with CE MRI and mammography combined was £28 284 compared to mammography. When only BRCA1 or the BRCA2 groups were considered, this cost would be reduced to £11 731 (CE MRI vs mammography) and £15 302 (CE MRI and mammography vs mammography). Results were most sensitive to the unit cost estimate for a CE MRI screening test. Contrast-enhanced MRI might be a cost-effective screening modality for women at high risk, particularly for the BRCA1 and BRCA2 subgroups. Further work is needed to assess the impact of screening on mortality and health-related quality of life.British Journal of Cancer (2006) 95, 801–810. doi:10.1038/sj.bjc.6603356 www.bjcancer.com [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
16. Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
- Author
-
Bramley, M., Clarke, R. B., Howell, A., Evans, D. G. R., Armer, T., Baildam, A. D., and Anderson, E.
- Subjects
BREAST cancer ,CANCER prevention ,ESTROGEN ,GENETIC mutation ,TAMOXIFEN ,STEROIDS ,EPITHELIUM ,TISSUES - Abstract
There is considerable interest in whether anti-oestrogens can be used to prevent breast cancer in women bearing mutations in the BRCA1 and BRCA2 genes. The effects of oestradiol (E2), tamoxifen (TAM) and fulvestrant (FUL) on proliferation and steroid receptor expression were assessed in normal breast epithelium taken from women at varying risks of breast cancer and implanted into athymic nude mice, which were treated with E2 in the presence and absence of TAM or FUL. Tissue samples were taken at various time points thereafter for assessment of proliferative activity and expression of oestrogen and progesterone receptors (ERalpha and PgR) by immunohistochemistry. Oestradiol increased proliferation in the breast epithelium from women carrying mutations in the BRCA1/2 genes, those otherwise at increased risk and those at population risk of breast cancer. This increase was reduced by both TAM and FUL in all risk groups. In the absence of E2, PgR expression was reduced in all risk groups but significantly more so in the BRCA-mutated groups. Subsequent E2 treatment caused a rapid, complete induction of PgR expression in the population-risk group but not in the high-risk or BRCA-mutated groups in which PgR induction was significantly delayed. These data suggest that the mechanisms by which E2 induces breast epithelial PgR expression are impaired in BRCA1/2 mutation carriers, whereas those regulating proliferation remain intact. We conclude that early anti-oestrogen treatment should prevent breast cancer in very high-risk women. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
17. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
- Author
-
Baser, M. E., Kuramoto, L., Woods, R., Joe, H., Friedman, J. M., Wallace, A. J., Ramsden, R. T., Olschwang, S., Bijlsma, E., Kalamarides, M., Papi, L., Kato, R., Carroll, J., Lázaro, C., Joncourt, F., Parry, D. M., Rouleau, G. A., and Evans, D. G. R.
- Subjects
NEUROFIBROMATOSIS ,GENETIC mutation ,PHENOTYPES ,TUMORS ,MEDICAL genetics ,LABORATORY mice - Abstract
Neurofibromatosis 2 (NF2) patients with constitutional splice site NF2 mutations have greater variability in disease severity than NF2 patients with other types of mutations; the cause of this variability is unknown. We evaluated genotype-phenotype correlations, with particular focus on tie location of splice site mutations, using mutation and clinical information on 831 patients from 528 NF2 families with identified constitutional NF2 mutations. The clinical characteristics examined were age at onset of symptoms of NF2 and number of intracranial meningiomas, which are the primary indices of the severity of NF2. Two regression models were used to analyse genotype-phenotype correlations. People with splice site mutations in exons 1-5 bad more severe disease than those with splice site mutations in exons 11-15. This result is compatible with studies showing that exons 2 and 3 are required for self-association of the amino terminal of the NF2 protein in vitro, and that deletions of exons 2 and 3 in transgenic and knockout mouse of NF2 cause a high prevalence of Schwann cell derived tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
18. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
- Author
-
Watson, M, Foster, C, Eeles, R, Eccles, D, Ashley, S, Davidson, R, Mackay, J, Morrison, P J, Hopwood, P, Evans, D G R, and Psychosocial Study Collaborators
- Subjects
PSYCHOLOGY of women ,BREAST cancer ,BREAST cancer surgery ,HUMAN chromosome abnormality diagnosis ,CANCER patients ,CANCER in women ,GENETIC testing ,AGE distribution ,ANXIETY ,BREAST tumors ,CLINICAL trials ,COMPARATIVE studies ,DISCRIMINATION in insurance ,DISEASE susceptibility ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,OVARIAN tumors ,QUESTIONNAIRES ,RESEARCH ,RISK management in business ,SEX distribution ,EVALUATION research ,BRCA genes ,GENETIC carriers ,PSYCHOLOGY ,CANCER & psychology - Abstract
This multi-centre UK study assesses the impact of predictive testing for breast and ovarian cancer predisposition genes (BRCA1/2) in the clinical context. In the year following predictive testing, 261 adults (59 male) from nine UK genetics centres participated; 91 gene mutation carriers and 170 noncarriers. Self-report questionnaires were completed at baseline (pre-genetic testing) and 1, 4 and 12 months following the genetic test result. Men were assessed for general mental health (by general health questionnaire (GHQ)) and women for general mental health, cancer-related worry, intrusive and avoidant thoughts, perception of risk and risk management behaviour. Main comparisons were between female carriers and noncarriers on all measures and men and women for general mental health. Female noncarriers benefited psychologically, with significant reductions in cancer-related worry following testing (P<0.001). However, younger female carriers (<50 years) showed a rise in cancer-related worry 1 month post-testing (P<0.05). This returned to pre-testing baseline levels 12 months later, but worry remained significantly higher than noncarriers throughout (P<0.01). There were no significant differences in GHQ scores between males and females (both carriers and noncarriers) at any time point. Female carriers engaged in significantly more risk management strategies than noncarriers in the year following testing (e.g. mammograms; 92%carriers vs 30%noncarriers). In the 12 months post-testing, 28%carriers had bilateral risk-reducing mastectomy and 31%oophorectomy. Oophorectomy was confined to older (mean 41?yrs) women who already had children. However, worry about cancer was not assuaged by surgery following genetic testing, and this requires further investigation. In all, 20%of female carriers reported insurance problems. The data show persistent worry in younger female gene carriers and confirm changes in risk management consistent with carrier status. Men were not adversely affected by genetic testing in terms of their general mental health.British Journal of Cancer (2004) 91, 1787-1794. doi:10.1038/sj.bjc.6602207 www.bjcancer.com Published online 26 October 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
19. Bilateral vestibular schwannomas in older patients: NF2 or chance?
- Author
-
Evans, D. G., Freeman, S., Gokhale, C., Wallace, A., Lloyd, S. K., Axon, P., Ward, C. L., Rutherford, S., King, A., Huson, S. M., and Ramsden, R. T.
- Subjects
NEUROFIBROMATOSIS 2 ,GENETIC mutation ,MENINGIOMA ,EPENDYMOMA ,MAGNETIC resonance imaging ,HETEROZYGOSITY - Abstract
Background Neurofibromatosis type 2 (NF2) is an autosomal dominant condition with high spontaneous mutation rate which predisposes to the development of multiple nerve sheath tumours (schwannomas), meningiomas and ependymoma. The cardinal feature and main diagnostic criterion for the diagnosis of NF2 remains the development of bilateral vestibular schwannoma (BVS). With increasing use of MRI screening the possibility of a 'chance' diagnosis of BVS has been mooted with a potential frequency of one in two million people in their lifetime. Until now, however, no evidence for such an event has been published. We aimed to demonstrate that chance occurrence can occur and to estimate its frequency among those with just BVS late in life. Methods Two vestibular schwannomas from the same patient were DNA sequenced and underwent loss of heterozygosity analysis. Results We show that a man who developed BVS, at ages 52 and 67 years developed these tumours sporadically by demonstrating that there were no molecular events in common between the two tumours. Furthermore from a database of over 1200 patients with NF2, we have estimated that ~25% of cases of BVS over 50 years and 50% over 70 years of age where no other features of NF2 are present represent a chance occurrence rather than due to an underlying mosaic or constitutional NF2 mutation. Conclusions Patients presenting with BVS later in life should be appraised of the potential likelihood they may not have NF2 and the resultant further reduction in risks of transmission to offspring. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
- Author
-
Evans, D. G., Howell, A., Ward, D., Lalloo, F., Jones, J. L., and Eccles, D. M.
- Subjects
BREAST cancer patients ,DISEASE prevalence ,GENETIC mutation ,GERM cells ,ONCOLOGY - Abstract
The article presents a study which examines the prevalence of breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) mutations in triple negative breast cancer (TNBC). It indicates that 11 out of 77 TNBCs unselected for age or family history had a germline mutation and one a somatic mutation in BRCA1, and three had BRCA2 mutations. It offers a guide to the probable outcome of testing in an isolated TNBC presenting for the first time in the oncology clinic.
- Published
- 2011
- Full Text
- View/download PDF
21. Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.
- Author
-
Evans, D. G. R., Maher, E. R., and Baser, M. E.
- Subjects
GENETIC mutation ,AGE ,DNA repair ,CANCER ,DISEASES in older people ,MUTAGENESIS - Abstract
It has been suggested that somatic mutations that accumulate due to an age related decline in the efficiency of DNA repair mechanisms might contribute to the increased incidence of cancer in older people. However, there is little direct evidence for this phenomenon. The spectra of germline and somatic mutations can be compared in cancer genes that cause inherited tumour syndromes and sporadic tumours, respectively. In addition, mosaic patients reflect the nature of mutations that occur in early development. Hence, we hypothesised that the "temporal mutation record" of a human cancer gene might provide insight into mechanisms of mutagenesis in the germline, in early development, and in adulthood. We compared the ratio of frameshift to nonsense mutations in three diseases that are related to the NF2 tumour suppressor gene: classic neurofibromatosis 2 (NF2), caused by germline NF2 mutations; mosaic NF2; and unilateral sporadic vestibular schwannoma (USYS), caused by somatic NF2 inactivation. Nonsense mutations predominated in both classic and mosaic NF2, but the ratio of nonsense to frameshift mutations was reversed in USYS. Moreover, in USYS patients, the ratio of somatic frameshift to nonsense mutations increased significantly with increasing age at diagnosis. This pattern is consistent with an age related decline in the efficiency of DNA repair mechanisms. Similar studies for other familial cancer genes may provide further evidence for this hypothesis. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
22. Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?
- Author
-
Evans, D. G., Clancy, T., Hill, J., and Tischkowitz, M.
- Subjects
- *
BRCA genes , *GENETIC mutation , *GENETICS of colon cancer - Abstract
A letter to the editor is presented in response to the article "BRCA1 and BRCA2 mutations and the risk for colorectal cancer," by V. Sopik and colleagues in the 2015 issue.
- Published
- 2016
- Full Text
- View/download PDF
23. Risk of breast cancer in male BRCA2 carriers.
- Author
-
Evans, D. G. R., Susnerwala, I., Dawson, J., Woodward, E., Maher, E. R., and Lalloo, F.
- Subjects
BREAST cancer ,GENETIC mutation ,CANCER risk factors ,CANCER in men ,CANCER patients - Abstract
The risk of breast cancer for unaffected men who test positive for a BRCA2 mutation is based on very few retrospective studies. We have used both retrospective and prospective analysis in 321 families with pathogenic BRCA2 mutations. Three breast cancers occurred in male first-degree relatives after family ascertainment in 4140 years of follow-up suggesting a risk of breast cancer to 80 years of 8.9%. A second analysis excluding index cases identified 16 breast cancers in 905 first-degree male relatives on which Kaplan-Meier analysis was performed after assigning carrier status. This analysis confirmed that breast cancer risk in men was 7.1% (SE 5.2-8.6%) by age 70 years and 8.4% (SE 6.2-10.6%) by age 80 years. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
24. SMARCB1 mutations are not a common cause of multiple meningiomas.
- Author
-
Hadfield, K. D., Smith, M. J., Trump, D., Newman, W. G., and Evans, D. G.
- Subjects
ACOUSTIC neuroma ,MENINGIOMA ,NEUROFIBROMATOSIS ,TUMORS ,GENETIC mutation - Abstract
Background Schwannomas and meningiomas are both part of the tumour spectrum of neurofibromatosis type 2 (NF2) and are associated with somatic loss of chromosome 22. They are also found commonly within the general population, unrelated to NF2. Germline SMARCB1 mutations have recently been identified as a pathogenic cause of a subset of familial schwannomatosis cases, and SMARCB1 is a candidate gene for causation of both schwannomas and meningiomas. Recently, Bacci et al reported a germline SMARCB1 mutation associated with familial schwannomatosis and multiple meningiomas. They concluded that SMARCB1 mutations can predispose to multiple meningiomas. Methods We screened the SMARCB1 gene in a panel of 47 patients with multiple meningioma unrelated to NF2. Results We found no germline mutations. Conclusion We conclude that while meningiomas may be associated with the schwannomatosis phenotype, SMARCB1 is not a major contributor to multiple meningioma disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Molecular genetic tests in surgical management of familial adenomatous polyposis.
- Author
-
Evans, D G, Evans, D, Hill, J, Dudding, T, Burn, J, and Maher, E R
- Subjects
- *
MOLECULAR biology , *GENETIC mutation , *SURGICAL anastomosis , *ADENOMATOUS polyposis coli ,RECTUM tumors - Published
- 1997
- Full Text
- View/download PDF
26. An Absence of Cutaneous Neurofibromas Associated with a 3-bp Inframe Deletion in Exon 17 of the NF1 Gene (c.2970-2972 delAAT): Evidence of a Clinically Significant NF1 Genotype-Phenotype Correlation.
- Author
-
Upadhyaya, Meena, Huson, S. M., Davies, M., Thomas, N., Chuzhanova, N., Giovannini, S., Evans, D. G., Howard, E., Kerr, B., Griffiths, S., Consoli, C., Side, L., Adams, D., Pierpont, M., Hachen, R., Barnicoat, A., Li, H., Wallace, P., Van Biervliet, J. P., and Stevenson, D.
- Subjects
- *
NEUROFIBROMATOSIS , *GENOTYPE-environment interaction , *PHENOTYPES , *FRECKLES , *GENETIC mutation , *GENES - Abstract
Neurofibromatosis type 1 (NF1) is characterized by café-au-lait spots, skinfold freckling, and cutaneous neurofibromas. No obvious relationships between small mutations (<20 bp) of the NF1 gene and a specific phenotype have previously been demonstrated, which suggests that interaction with either unlinked modifying genes and/or the normal NF1 allele may be involved in the development of the particular clinical features associated with NF1. We identified 21 unrelated probands with NF1 (14 familial and 7 sporadic cases) who were all found to have the same c.2970-2972 delAAT(p.990delM) mutation but no cutaneous neurofibromas or clinically obvious plexiform neurofibromas. Molecular analysis identified the same 3-bp inframe deletion (c.2970-2972 delAAT) in exon 17 of the NF1 gene in all affected subjects. The ΔAAT mutation is predicted to result in the loss of one of two adjacent methionines (codon 991 or 992) (ΔMet991), in conjunction with silent ACA→ACG change of codon 990. These two methionine residues are located in a highly conserved region of neurofibromin and are expected, therefore, to have a functional role in the protein. Our data represent results from the first study to correlate a specific small mutation of the NF1 gene to the expression of a particular clinical phenotype. The biological mechanism that relates this specific mutation to the suppression of cutaneous neurofibroma development is unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.